1. PRE-NTM — Nortriptyline + Pregabalin (SR) + Methylcobalamin
2. Cuipda (pink strip) — likely Clonazepam/Etizolam combination (need to verify label)
3. TIN CR 25 — Paroxetine CR 25 mg
4. SUCCORMAT — Diclofenac Potassium + Metaxalone

PharmD Medication Review

Medications Identified

1. PRE-NTM — Pregabalin (SR) + Nortriptyline + Methylcobalamin

Mechanism of Action

• Pregabalin (SR): Binds to α2-δ subunit of voltage-gated calcium channels → ↓ release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) → modulates nociceptive signal transmission
• Nortriptyline (TCA): Inhibits reuptake of norepinephrine and serotonin; secondary analgesic mechanism via descending pain pathway modulation; also blocks Na⁺ channels
• Methylcobalamin: Active form of Vitamin B12 → promotes myelin synthesis and axonal regeneration in peripheral nerves

Therapeutic Indication

Dosing (Typical)

• Pregabalin SR: 75–150 mg once daily (SR formulation allows once-daily dosing)
• Nortriptyline: 10–25 mg at night (low-dose analgesic use)
• Methylcobalamin: 1500 mcg/day

PharmD Counseling Points

• Take at bedtime — nortriptyline causes sedation
• Pregabalin: do not stop abruptly (withdrawal seizures risk); taper over ≥1 week
• Warn about: dizziness, somnolence, weight gain, dry mouth, constipation, blurred vision
• Nortriptyline has anticholinergic effects — caution in elderly (Beers Criteria), BPH, glaucoma
• Monitor ECG at baseline if cardiac risk factors (TCA prolongs QTc)
• Avoid alcohol (additive CNS depression)

Drug Interactions ⚠️

• Pregabalin + CNS depressants → additive sedation
• Nortriptyline + MAOIs → hypertensive crisis (contraindicated; 14-day washout needed)
• Nortriptyline + Paroxetine (TIN CR) → SIGNIFICANT INTERACTION — Paroxetine is a potent CYP2D6 inhibitor; nortriptyline is a CYP2D6 substrate → ↑ nortriptyline plasma levels → risk of TCA toxicity (arrhythmia, seizures)

2. Cuipda Strip (Pink) — Likely Clonazepam + Methylcobalamin or similar neurological combination

If Clonazepam component:

• MOA: Enhances GABA-A receptor activity → ↑ Cl⁻ influx → neuronal hyperpolarization → anticonvulsant, anxiolytic, muscle relaxant
• Indications: Epilepsy, anxiety, neuropathic pain (adjunct), restless leg syndrome
• Counseling: Benzodiazepine — dependence risk; do NOT stop abruptly (seizure threshold lowered); sedation, cognitive impairment
• Interaction with Paroxetine: Paroxetine inhibits CYP3A4 mildly → may ↑ clonazepam levels

3. TIN CR 25 — Paroxetine Controlled Release 25 mg

Mechanism of Action

Therapeutic Indications

Dosing

• Starting: 12.5 mg/day CR → titrate to 25 mg/day
• Max: 62.5 mg/day (depression), 75 mg/day (OCD)

PharmD Counseling Points

• Take in the morning with food (nausea reduction)
• Therapeutic effect delayed 2–4 weeks — patient must be counseled on adherence
• Do not crush or split CR tablet
• Discontinuation syndrome is most severe among all SSRIs with paroxetine (shortest half-life ~21 hours, no active metabolite) → taper slowly, never stop abruptly
• Monitor for: suicidal ideation (first 2 weeks especially), sexual dysfunction, insomnia, weight gain, hyponatremia (SIADH — especially in elderly)
• Paroxetine is Category D in pregnancy (cardiac malformations risk — ductus arteriosus)

Critical Drug Interaction ⚠️

• Paroxetine (potent CYP2D6 inhibitor) + Nortriptyline (CYP2D6 substrate) → TCA toxicity risk
  • Recommendation: Monitor nortriptyline plasma levels; consider dose reduction of nortriptyline or substitute with a less interaction-prone TCA
• Paroxetine + Tramadol/Triptans → serotonin syndrome risk

4. SUCCORMAT — Diclofenac Potassium + Metaxalone

Mechanism of Action

• Diclofenac Potassium: Non-selective COX-1 and COX-2 inhibitor → ↓ prostaglandin synthesis → analgesic + anti-inflammatory + antipyretic. Potassium salt = faster absorption than sodium salt (used for acute pain)
• Metaxalone: Central muscle relaxant — MOA not fully established; CNS depression at brainstem/spinal cord level → skeletal muscle relaxation (not direct peripheral action)

Therapeutic Indication

Dosing

• Diclofenac K: 50 mg TID (with meals)
• Metaxalone: 800 mg TID–QID

PharmD Counseling Points

• Take after food — diclofenac is gastric irritant (COX-1 inhibition → ↓ mucosal prostaglandins)
• Use for the shortest duration at lowest effective dose (NSAID risk: GI bleed, peptic ulcer, renal impairment, cardiovascular events)
• Avoid in: renal impairment, peptic ulcer disease, heart failure, asthma (aspirin-sensitive)
• Metaxalone causes sedation, dizziness — avoid driving
• Monitor: LFTs (both diclofenac and metaxalone are hepatotoxic — rare but possible)
• Avoid with anticoagulants (↑ bleeding risk) and other NSAIDs

Drug Interactions ⚠️

• Diclofenac + SSRIs (Paroxetine): ↑ risk of GI bleeding (SSRIs inhibit platelet aggregation via serotonin depletion)
• Diclofenac + ACE inhibitors/ARBs: ↓ antihypertensive effect + ↑ nephrotoxicity
• Metaxalone + CNS depressants/Pregabalin/Nortriptyline: Additive CNS depression

⚠️ Critical Polypharmacy Alert — PharmD Summary

Clinical Context Assessment

• Neuropathic pain (PRE-NTM — pregabalin + nortriptyline)
• Comorbid depression or anxiety disorder (Paroxetine CR)
• Acute musculoskeletal/spinal pain component (Diclofenac + Metaxalone)

PharmD Recommendations

1. Mandatory: ECG before and after initiating nortriptyline, especially alongside paroxetine
2. Nortriptyline dose adjustment given CYP2D6 inhibition by paroxetine — consider reducing to 10 mg/day and monitoring
3. Add PPI (e.g., pantoprazole 40 mg OD) to protect gastric mucosa given concurrent NSAID + SSRI use
4. Patient counseling on sedation from the combination (pregabalin + nortriptyline + metaxalone) — advise no driving
5. SUCCORMAT is short-term only — define a clear stop date; reassess after 5–7 days
6. Monitor: LFTs (metaxalone + diclofenac), renal function (NSAID), serum sodium (paroxetine/SIADH risk), plasma nortriptyline levels if available
7. Pregnancy counseling if applicable — paroxetine is Category D; NSAIDs avoid in 3rd trimester

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Bradley and Daroff's Neurology in Clinical Practice | Harrison's Principles of Internal Medicine 22E